Geraldine Cambridge
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Jo Cambridge)
Doctor Geraldine Cambridge, also known as Jo Cambridge, is Principal Research Fellow, Inflammation, Division of Medicine, Faculty of Medical Sciences, University College London in the United Kingdom. She has previously worked with Jonathan Edwards in rheumatoid arthritis Rituximab research.
She spoke at the Invest in ME International ME Conferences in 2015 and 2016 about immunoregulation in patients with ME and the IiME Rituximab study.[1][2]
Dr. Cambridge was the Principal Investigator of the Invest in ME UK RITUXIMAB Clinical Trial and B-Cell Research, along with a team from Rayne Institute, University College London.
Awards[edit | edit source]
- 2016 Ramsay Award Program grant recipient, sponsored by the Solve ME/CFS Initiative. This grant, shared with Christopher Armstrong, University of Melbourne, and Fane Mensah, University College London, will focus on the metabolic analysis of B-Cell maturation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[3][4]
Talks and interviews[edit | edit source]
- 2015, Speaker at the 10th Invest in ME International ME Conference[5] - DVD available
- 2016, Speaker at the 11th Invest in ME International ME Conference on "Immunoregulation in patients with ME"[6] - DVD available
- 2017, Speaker at the 12th Invest in ME International ME Conference on "Immunoregulation in patients with ME"[7] - DVD available
- 2017, CARE4ME Conference | Part Six[8]
- 13 Mar 2019, Abstract Presentation: Differences Between Immunophenotype of B Cells from Healthy Controls & Patients with ME/CFS given at the International Research Symposium, Geelong, Australia, sponsored by Emerge Australia[9]
Notable studies[edit | edit source]
- 2016, Extended B cell phenotype in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A cross-sectional study[10] (Full Text)
- 2017, Review - Chronic fatigue syndrome and the immune system: Where are we now?[11] (Abstract)
- 2018, CD24 Expression and B Cell Maturation Shows a Novel Link With Energy Metabolism: Potential Implications for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[12] (Full Text)
See also[edit | edit source]
References[edit | edit source]
- ↑ "IIMEC11 International ME Conference 2016". Invest in ME Research. Retrieved February 18, 2020.
- ↑ "IIMEC10 International ME Conference 2015". Invest in ME Research. Retrieved February 18, 2020.
- ↑ "2016 Ramsay Award Program Results". Solve ME/CFS Initiative. Retrieved February 18, 2020.
- ↑ "Metabolic Analysis of B-Cell Maturation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Solve ME/CFS Initiative. December 7, 2016. Retrieved February 18, 2020.
- ↑ "IIMEC10 International ME Conference 2015". Invest in ME Research. Retrieved February 18, 2020.
- ↑ "IIMEC11 International ME Conference 2016". Invest in ME Research. Retrieved February 18, 2020.
- ↑ "IIMEC12 International ME Conference 2017". Invest in ME Research. Retrieved February 18, 2020.
- ↑ CARE4ME Conference | Part Six (Prof. Dr. Jo Cambridge), retrieved February 18, 2020
- ↑ "Abstract Presentation: Differences Between Immunophenotype of B Cells from Healthy Controls & Patients with ME/CFS". Emerge Australia - ME/CFS International Research Symposium. Retrieved February 18, 2020.
- ↑ Mensah, Fane; Bansal, Amolak; Berkovitz, Saul; Sharma, Arti; Reddy, Venkat; Leandro, Maria; Cambridge, Geraldine (2016), "Extended B cell phenotype in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A cross-sectional study", Clinical and Experimental Immunology, 184 (2): 237-247, doi:10.1111/cei.12749
- ↑ Mensah, Fane; Bansal, Amolak; Ford, Brian; Cambridge, Geraldine (2017), "Chronic fatigue syndrome and the immune system: Where are we now?", Neurophysiologie Clinique, 47 (2): 131-138, doi:10.1016/j.neucli.2017.02.002
- ↑ Mensah, Fane F.K.; Armstrong, Christopher W.; Reddy, Venkat; Bansal, Amolak S.; Berkovitz, Saul; Leandro, Maria J.; Cambridge, Geraldine (2018). "CD24 Expression and B Cell Maturation Shows a Novel Link With Energy Metabolism: Potential Implications for Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Frontiers in Immunology. 9. doi:10.3389/fimmu.2018.02421. ISSN 1664-3224.
